Klerimed

Clarithromycin, the active ingredient in Klerimed, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections in adults and children when prescribed by a qualified health professional and is indicated for community‑acquired respiratory infections, skin and soft‑tissue infections, and for use in combination regimens against Helicobacter pylori.

GNH USA supplies Klerimed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory conformity across all markets.

Clarithromycin is used to treat bacterial infections affecting various organ systems.

- Community‑acquired pneumonia: eliminates the causative bacteria, improving respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation by eradicating the infecting organisms. - Acute exacerbations of chronic bronchitis: shortens illness duration and alleviates cough. - Skin and soft‑tissue infections: clears Staphylococcus and Streptococcus species from affected tissues. - Helicobacter pylori eradication (with other agents): contributes to ulcer healing by suppressing bacterial colonisation.

Clarithromycin may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Abdominal pain - Altered taste perception - Headache

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reactions - QT interval prolongation and cardiac arrhythmias - Hepatotoxicity, including elevated liver enzymes - Clostridioides difficile‑associated diarrhea - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Drug‑induced liver injury

Before initiating therapy, clinicians should consider several safety aspects.

- Assess renal and hepatic function: adjust therapy if impairment is present. - Avoid use in patients with known macrolide hypersensitivity: discontinue immediately if reaction occurs. - Monitor cardiac rhythm in patients at risk for QT prolongation: consider baseline ECG. - Use caution during pregnancy: limited data, weigh benefits against potential risks. - Avoid concomitant use with strong CYP3A4 inhibitors: may increase clarithromycin plasma levels. - Store below 25°C: keep in the original pack, protect from moisture.

Clarithromycin interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir): risk of clarithromycin toxicity. - Antiarrhythmics such as amiodarone or quinidine: may cause serious cardiac events. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): increased risk of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: clarithromycin may enhance anticoagulant effect; monitor INR. - Theophylline: increased plasma concentrations; watch for toxicity signs. - Carbamazepine: may reduce clarithromycin levels; monitor clinical response.